GlassScriptPhysician profile
Michael Sean Conley
NPI 1316010192
$755.68
in general payments reported to CMS, 2019-2025
15 companies · $200 in 2025
The $200 reported for 2025 was more than what a typical Psychiatry provider received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $134 · 2020: $36.85 · 2021: $95.45 · 2022: $44.88 · 2023: $42.87 · 2024: $201 · 2025: $200.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $444.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $444.28 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $103.73 | 2024-2025 | Cobenfy |
| Lundbeck LLC | $102.72 | 2021-2024 | Rexulti |
| Abbvie INC. | $96.86 | 2024-2025 | |
| Sunovion Pharmaceuticals INC. | $78.41 | 2019-2020 | |
| Otsuka America Pharmaceutical, INC. | $67.71 | 2019-2023 | Rexulti |
| Neurocrine Biosciences, INC. | $62.01 | 2024 | Ingrezza |
| Janssen Pharmaceuticals, INC | $45.73 | 2019-2021 | |
| Allergan, INC. | $40.00 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $36.72 | 2022-2024 | Trintellix |
| Almatica Pharma LLC | $33.73 | 2025 | Loreev Xr |
| Axsome Therapeutics, INC. | $23.10 | 2025 | Auvelity |
| Tris Pharma INC | $17.49 | 2023 | Dyanavel Xr |
| Vertical Pharmaceuticals, LLC | $16.35 | 2025 | Relexxii |
| Astellas Pharma US INC | $15.70 | 2021 | |
| Hologic Sales and Service, LLC | $15.42 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Conley listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.